News
Public · Published
Guggenheim maintains Neurocrine Biosciences at Buy, raises price target to $224 from $207
Guggenheim kept its Buy rating on Neurocrine Biosciences and raised its price target to $224 from $207. The new target is 8.2% higher and implies 35.9% upside from the November 3 closing price of $164.85. Five recent analyst targets ranged from $185 to $220.
Published:
Updated:
What happened
Guggenheim kept its Buy rating on Neurocrine Biosciences and raised its price target to $224 from $207. The new target is 8.2% higher and implies 35.9% upside from the November 3 closing price of $164.85. Five recent analyst targets ranged from $185 to $220.
Confirmed
Global impact / market context
The higher target signals that Guggenheim sees more potential value in Neurocrine shares, which could influence investor expectations and trading decisions. However, a price target is an analyst estimate, not a promised outcome, and other recent analysts set targets both below and near Guggenheim’s new figure.
Analyst inference
Recent analyst opinions on Neurocrine Biosciences varied, with reported price targets ranging from $185 to $220 and ratings including Equal-Weight, Outperform, Buy, and Overweight. Guggenheim’s $224 target exceeds that range, which may shape investor expectations but does not establish future performance.
Analyst inference
What to watch
- Compare future analyst targets and ratings with Guggenheim’s $224 estimate to see whether other firms also raise their expectations or retain lower valuations. Analyst inference
- Check subsequent company updates for evidence that could affect revenue, costs, or expected earnings; the supplied article gives no business results or reasons for Guggenheim’s change. Analyst inference
- The reported target implies 35.9% upside from the November 3 close of $164.85, but it remains an analyst estimate rather than a guaranteed share-price outcome. Confirmed
Evidence
- Original source link unavailable